We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Preoperative Glycemic Control Reduces Postoperative Infections

By HospiMedica staff writers
Posted on 05 May 2006
Long-term glycemic control in diabetics is linked to a decrease in post-operative infections across a variety of major noncardiac surgical procedures, a new study finds. More...


The retrospective cohort study examined 490 mainly non-black male patients with a mean age of 71 for a period of six months prior to surgery. Biannual HbA1c levels were selected as the criterion, as suggested by the American Diabetes Association, who recommends this testing frequency for patients with well-controlled glucose.

HbA1c levels, age, operation length, American Society of Anesthesiologists class, and non-clean wound class emerged as significantly related to postoperative infections. The importance of serious comorbidity was also confirmed. The type of diabetic treatment was not significant, as were assessment on the Activities of Daily Living (ADL) scale and urgency of the case, the researchers reported. The researchers concluded that good pre-operative glycemic control six months prior to surgery was associated with a decreased rate of infections. The results were reported in the April 2006 edition of Archives of Surgery.

"Strategies to improve glycemic control prior to elective surgery can be employed to decrease infections and improve overall outcomes for diabetic surgical patients,” said lead author Ronnie Ann Rosenthal, M.D., of Yale University School of Medicine (New Haven, CT, USA), and colleagues.

Why pre-operative glycemic control is linked to reduced post-operative infections can be considered from two perspectives, the investigators reported.. Glucose is a proinflammatory mediator shown to have a wide variety of effects, including stimulating cytokine production and inhibiting endothelial nitric oxide levels. The other possible explanation for the decrease is the overall improvement in the general health and metabolic milieu of the well-controlled diabetic patient.



Related Links:
Yale University School of Medicine

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Half Apron
Demi
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.